Roche Holding AG is a holding company for Roche, a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.

According to the law firm press release, the lawsuit alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the combination of Perjeta and Herceptin is only marginally more effective than Herceptin alone in preventing breast cancer; and (2) as a result, Defendants’ statements about Roche’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On September 22, 2017, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on March 5, 2018. Defendants filed a Motion to Dismiss the amended Complaint on June 4. On September 24, the Court issued an Order granting Defendants' Motion to Dismiss. Lead Plaintiff was given leave to file amend the Complaint. On October 15, Lead Plaintiff filed a second amended Complaint. Defendants filed a Motion to Dismiss the second amended Complaint on December 21. On April 3, 2019, the Court issued an Order granting Defendants' Motion to Dismiss. Plaintiff was given leave to amend the Complaint. Plaintiff filed a third amended Complaint on April 24. Defendants filed a Motion to Dismiss the third amended Complaint on May 8. On June 17, 2019, the Court issued an Order granting Defendants' Motion to Dismiss.